Sally-Ann is a highly experienced scientist and project leader with over 25 years of experience in Research and Development.
Her expertise covers diagnostic and pharmaceutical fields, with experience in pre-clinical and clinical development across different disciplines, with a focus on translational research.
Following a PhD in surgical research, Sally-Ann joined GE Healthcare in 1999 as a biologist to develop and subsequently lead projects developing new diagnostic imaging agents. In 2007, she joined AstraZeneca to lead a team (initially in the UK and then globally) evaluating translational imaging biomarkers with the aim of providing earlier clinical readouts to accelerate drug development. In 2016 Sally-Ann joined Tangerine Holdings to lead Research and Development to support their existing product portfolio and drive new product development.
She has over 40 publications, 1 book chapter, 8 invited presentations and 10 published patents.
Sally-Ann joined the Medicines Discovery Catapult in 2021 as part of the Virtual Research and Development team to help SMEs develop their strategies and re-disk their programmes.